Kelly Lawrence W & Associates Inc. CA held its stake in shares of Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,250 shares of the company’s stock at the close of the 2nd quarter. Kelly Lawrence W & Associates Inc. CA’s holdings in Eli Lilly and were worth $103,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of LLY. Waldron LP lifted its position in shares of Eli Lilly and by 46.7% during the 1st quarter. Waldron LP now owns 4,948 shares of the company’s stock worth $415,000 after purchasing an additional 1,574 shares during the last quarter. Sfmg LLC lifted its holdings in shares of Eli Lilly and by 6.4% during the first quarter. Sfmg LLC now owns 4,238 shares of the company’s stock worth $356,000 after buying an additional 256 shares during the last quarter. Vantage Investment Partners LLC lifted its holdings in shares of Eli Lilly and by 504.5% during the first quarter. Vantage Investment Partners LLC now owns 139,892 shares of the company’s stock worth $11,766,000 after buying an additional 116,752 shares during the last quarter. DT Investment Partners LLC lifted its holdings in shares of Eli Lilly and by 17.3% during the first quarter. DT Investment Partners LLC now owns 16,726 shares of the company’s stock worth $1,407,000 after buying an additional 2,467 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI lifted its holdings in shares of Eli Lilly and by 48.6% during the first quarter. Commerzbank Aktiengesellschaft FI now owns 105,415 shares of the company’s stock worth $8,866,000 after buying an additional 34,482 shares during the last quarter. 75.72% of the stock is currently owned by institutional investors.

Several brokerages have recently issued reports on LLY. Jefferies Group LLC restated a “buy” rating and issued a $89.00 price objective on shares of Eli Lilly and in a research note on Monday, September 11th. BMO Capital Markets reiterated an “underperform” rating and set a $71.00 target price (down from $73.00) on shares of Eli Lilly and in a research note on Wednesday, September 6th. Piper Jaffray Companies reissued an “overweight” rating and issued a $105.00 price target (up from $103.00) on shares of Eli Lilly and in a report on Friday, September 8th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a report on Monday, July 17th. Finally, Morgan Stanley reissued a “hold” rating and issued a $86.00 price target on shares of Eli Lilly and in a report on Friday, September 15th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company. Eli Lilly and currently has an average rating of “Hold” and a consensus target price of $88.27.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 195,000 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $85.14, for a total value of $16,602,300.00. Following the sale, the insider now owns 123,513,247 shares in the company, valued at $10,515,917,849.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders sold 785,000 shares of company stock worth $65,153,600. Company insiders own 0.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/04/eli-lilly-and-company-lly-stake-held-by-kelly-lawrence-w-associates-inc-ca.html.

Eli Lilly and Company (LLY) opened at 86.45 on Wednesday. The company has a 50 day moving average price of $81.60 and a 200-day moving average price of $82.05. The company has a market capitalization of $91.20 billion, a PE ratio of 37.41 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $86.72.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.86 EPS. On average, analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current year.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.